FDA Authorizes New Novavax Vaccine Targeting Omicron Variant

Updated COVID-19 vaccine approved for individuals aged 12 and older, alongside guidance on fall flu shots and RSV protection.

The new Novavax vaccine targets the Omicron JN1 strain and replaces the previous formula.
Eligible individuals include those aged 12 and older, with specific dosing for unvaccinated and previously vaccinated people.
Health officials emphasize the importance of fall vaccinations, including flu and RSV, to prevent severe respiratory illnesses.
Pharmacists recommend timing flu shots for late September or early October to maximize immunity during peak season.
The CDC notes that while COVID-19 vaccines reduce severe disease, staying up to date is crucial for ongoing protection.